# Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

> **NCT00073749** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 79 (actual)

## Conditions studied

- Lymphoma, B-Cell

## Interventions

- **DRUG:** Inotuzumab ozogamicin [CMC-544]

## Key facts

- **NCT ID:** NCT00073749
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2018-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00073749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00073749, "Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00073749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*